Shanghai Biomabs Pharmaceutical

• Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® .

  Phase 3, Completed, 278 people, 19 Oct 2020

• NCT03925051

  Phase 1, Completed, 132 people, 23 Apr 2019

• NCT03478111

  Phase 3, Completed, 390 people, 27 Mar 2018

Sources: clinicaltrials.gov